The local medical community is buzzing with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing significant results in scientific trials for addressing obesity. This treatment https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/